Advertisement

Related Videos

Opportunities to Optimize Cancer Policies Panel Discussion

Sarah Yim, MD, on Clinical Development of Biosimilars: Lessons for Interventional Pharmacoeconomics

Varsha Gandhi, PhD, on Ibrutinib

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Welcome and Introduction to Vi3C

Advertisement

Advertisement




Mar
27
Today In Oncology
AI As Collaborator in Cancer Research and in Clinical Care
AI Use in Cancer Diagnosis, Prognosis, and Treatment: Are We There Yet?
Neoadjuvant GOLP in High-Risk Intrahepatic Cholangiocarcinoma
Gedatolisib-Based Regimens in HR-Positive HER2-Negative PIK3CA Wild-Type Advanced Breast Cancer
Hyperplasia and the Link Between Obesity and Cancer
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo